Generics and biosimilars are reimbursed differently, causing providers to prefer lower-cost generics and higher-priced biologics, authors of a study and opinion piece contend. There is pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback